Answers are grounded in this paper and cite their sources.
Objectives We report the cases of 2 siblings diagnosed with B-cell ALL within a span of 21 months, present the genetic investigations and describe the challenges of care coordination and the holistic considerations when managing two simultaneous treatment journeys. Methods Electronic patient records were reviewed, and semi-structured interviews were conducted to qualitatively assess the challenges faced by the family and the multidisciplinary teams involved. Results Case 1 involved a 2-year-old male patient diagnosed with pre-B ALL, characterized by hyperdiploid cytogenetics. The patient received treatment according to the UKALL 2019 guidelines, with a switch to regimen C due to high minimal residual disease (MRD) levels at the end of induction. Additionally, two Blinatumomab cycles were administered instead of interim maintenance due to post-chemotherapy complications of pancreatitis and typhlitis. While he was on maintenance chemotherapy, his 14- year-old sister (Case 2) was diagnosed with pre-B ALL with iAMP21 cytogenetics after presenting with a supraclavicular lump. She was also managed under the UKALL 2019 regimen C. Whole genome sequencing was performed for both siblings, which did not reveal any germline mutations or other identifiable genetic predispositions. Challenges in simultaneously managing the treatment of two siblings mainly related to the coordination and rationalisation of numerous acute and elective clinical attendances (including clinic appointments, chemotherapy administrations, blood tests, therapy sessions, emergency admissions) at various settings; 2 different Primary Treatment Centers, the Pediatric Oncology Shared Care Unit, home and schools. The successful navigation of these intertwined and complex treatment journeys heavily relied on flexible planning strategies and effective communication between three multidisciplinary teams. Conclusion While the overall familial risk for haematological malignancies is typically low,¹ the occurrence of acute lymphoblastic leukemia (ALL) in siblings may be more common than previously believed. This report highlights the significance of Genomics Tumour Advisory Boards in facilitating comprehensive genetic testing in such cases, and underscores the critical role of clear and continuous multidisciplinary teamwork in providing holistic support and coordinating treatment journeys. References Amit Sud, Subhayan Chattopadhyay, Hauke Thomsen, Kristina Sundquist, Jan Sundquist, Richard S Houlston, Kari Hemminki. Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. Blood 2019;134(12):960–969.
No takes yet. Share an insight, caveat, or question.
Tsouana et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: